Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events.

Raschi, Emanuel; Casula, Manuela; Cicero, Arrigo F G; Corsini, Alberto; Borghi, Claudio; Catapano, Alberico

Raschi, Emanuel; Casula, Manuela; Cicero, Arrigo F G; Corsini, Alberto; Borghi, Claudio; Catapano, Alberico.

Afiliación

Raschi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy. Electronic address: emanuel.raschi@unibo.it.
Casula M; Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; IRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy.
Cicero AFG; Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy; IRCCS AOU S. Orsola-Malpighi, Bologna, Italy.
Corsini A; Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Borghi C; Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy; IRCCS AOU S. Orsola-Malpighi, Bologna, Italy.
Catapano A; IRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy.

Pharmacol Ther ; 250: 108507, 2023 Oct.

Article en En | MEDLINE | ID: mdl-37567512

Palabras clave

Bempedoic acid; Evinacumab; Inclisiran; LDL-cholesterol; Lomitapide; Major adverse cardiovascular events; PCSK9 inhibitors; Statins

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Risk_factors_studies Idioma: En Revista: Pharmacol Ther Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google